EU-MALARIA-FUND
7.10.2021 10:02:08 CEST | Business Wire | Press release
On 30 September, the EU Malaria Fund (EUMF) concluded its investment activities at a high-level online event by finalizing its investments into four innovative companies active in malaria R&D. The EUMF has successfully expanded the pipeline of malaria R&D by funding nine promising and innovative malaria projects, covering treatments, vaccines, and diagnostics.
The COVID-19 pandemic has changed the game and led to the deployment of four EMA-approved, safe, and effective vaccines within less than 12 months. With this novel need to develop a large project on a now proven technology platform, the EUMF has successfully accomplished its mission earlier than expected. The EUMF will now enter its post-investment period.
The EUMF is grateful to the European Commission and the European Investment Bank (EIB), the major contributors to the Fund through the InnovFin EU programme funded by EU Horizon 2020 and the European Fund of Strategic Investments.
Other investors and supporters include the Investitionsbank Berlin, the Bill & Melinda Gates Foundation, Fondazione Monte Dei Paschi Di Siena, Jacques und Gloria Gossweiler Stiftung, Invethos AG, FINDdx, and Novartis AG. The fund was initiated by kENUP Foundation in cooperation with EIB and is managed by IBB Group Berlin.
The investments would not have been possible without the excellent work of the Funds Scientific Advisory Council and the Investment Decision Committee.
On 26 July, BioNTech SE announced the start of its Malaria project which aims at the development of a safe and highly effective malaria vaccine and the implementation of sustainable vaccine supply solutions on the African continent. The program was initiated by kENUP Foundation. Additional such programmes are currently being conceived and could cover other infectious diseases, such as tuberculosis and HIV.
Pedro Alonso , Director of the World Health Organization’s Global Malaria Programme, states: “The EU Malaria Fund is a great example how innovative new instruments can ultimately lead to impact. Malaria is the biggest killer of mankind. It affects the poorest and contributes to keeping them in poverty. I would like to thank everyone involved in the EU Malaria Fund project for their contribution to fighting malaria.”
Mariya Gabriel , Commissioner for Innovation, Research, Culture, Education and Youth: “Malaria is one of the most challenging diseases to beat and all efforts to find new vaccines or preventive means are important. For decades the European Union’s research and innovation programmes provided support to contribute to the global research agenda for malaria and we are committed to continue these efforts.“
Werner Hoyer , President of the European Investment Bank: “Malaria kills more than 1000 people each day – most of them children. Every step in the fight against the disease is welcome and much needed. Thanks to the successful work of the EU Malaria Fund, which financed nine promising projects, we significantly increased our chances to find new medications, diagnostics and vaccines. I am proud that the EIB is part of this effort.”
The video recording and more information can be found at https://www.controlmalaria.eu/news#conclusion
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005395/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom